Genetic and epigenetic bases of the relationship between reduced OCT1 expression and poor response to sorafenib in hepatocellular carcinoma and cholangiocarcinoma

被引：1
|
作者：
Al-Abdulla, R. [1 ]
Lozano, E. [2 ]
Macias, R. I. [2 ]
O'Rourke, C. J. [3 ]
Perez, M. J. [2 ]
Serrano, M. A. [2 ]
Romero, M. R. [2 ]
Monte, M. J. [2 ]
Herraez, E. [2 ]
Briz, O. [2 ]
Banales, J. M. [4 ]
Bujanda, L. [4 ]
Geier, A. [5 ]
Andersen, J. B. [3 ]
Marin, J. J. [2 ]
机构：
[1] Univ Salamanca, IBSAL, Expt Hepatol & Drug Targeting HEVEFARM, Salamanca, Spain
[2] Univ Salamanca, Expt Hepatol & Drug Targeting HEVEFARM, IBSAL, CIBERehd, Salamanca, Spain
[3] Univ Copenhagen, Biotech Res & Innovat Ctr, Dept Hlth & Human Sci, Copenhagen, Denmark
[4] Univ Basque Country, San Sebastian Univ Hosp, Biodonostia Biomed Res Inst, Dept Hepatol & Gastroenterol, San Sebastian, Spain
[5] Wurzburg Univ Hosp, Dept Med 2, Div Hepatol, Wurzburg, Germany
来源：
JOURNAL OF HEPATOLOGY | 2017年 / 66卷 / 01期
关键词：
D O I：
10.1016/S0168-8278(17)31309-0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
FRI-115
引用
收藏
页码：S462 / S463
页数：2
相关论文
共 44 条
  • [1] Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment
    Daniel Grimm
    Jonas Lieb
    Veronika Weyer
    Johanna Vollmar
    Felix Darstein
    Anja Lautem
    Maria Hoppe-Lotichius
    Sandra Koch
    Arno Schad
    Jörn M. Schattenberg
    Marcus A. Wörns
    Arndt Weinmann
    Peter R. Galle
    Tim Zimmermann
    BMC Cancer, 16
  • [2] Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment
    Grimm, Daniel
    Lieb, Jonas
    Weyer, Veronika
    Vollmar, Johanna
    Darstein, Felix
    Lautem, Anja
    Hoppe-Lotichius, Maria
    Koch, Sandra
    Schad, Arno
    Schattenberg, Joern M.
    Woerns, Marcus A.
    Weinmann, Arndt
    Galle, Peter R.
    Zimmermann, Tim
    BMC CANCER, 2016, 16
  • [3] The absence of OCT1 at the plasma membrane of tumor cells is associated with a worse response of hepatocellular carcinoma to sorafenib
    Geier, A.
    Al-Abdulla, R.
    Macias, R.
    Bettinger, D.
    Weiss, J.
    Bantel, H.
    Jahn, D.
    Ascensio, M.
    Alonso-Pena, M.
    Al-Aqil, F.
    Marin, J.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S230 - S230
  • [4] Cellular Uptake of Sorafenib into Hepatocellular Carcinoma Cells Is Independent of Human Organic Cation Transporter 1 (OCT1)
    Neul, C.
    Baker, S. D.
    Sparreboom, A.
    Schaeffeler, E.
    Schwab, M.
    Nies, A. T.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2015, 388 : S23 - S23
  • [5] Expression of SLC22A1 Variants May Affect the Response of Hepatocellular Carcinoma and Cholangiocarcinoma to Sorafenib
    Herraez, Elisa
    Lozano, Elisa
    Macias, Rocio I. R.
    Vaquero, Javier
    Bujanda, Luis
    Banales, Jesus M.
    Marin, Jose J. G.
    Briz, Oscar
    HEPATOLOGY, 2013, 58 (03) : 1065 - 1073
  • [6] The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma
    Geier, Andreas
    Macias, Rocio I. R.
    Bettinger, Dominik
    Weiss, Johannes
    Bantel, Heike
    Jahn, Daniel
    Al-Abdulla, Ruba
    Marin, Jose J. G.
    ONCOTARGET, 2017, 8 (09) : 15846 - 15857
  • [7] THE MAGNITUDE OF THE RESPONSE OF HEPATOCELLULAR CARCINOMA AND CHOLANGIOCARCINOMA TO SORAFENIB IS AFFECTED BY THE EXPRESSION OF INACTIVATING VARIANTS IN THE SLC22A1 GENE
    Herraez, E.
    Briz, O.
    Lozano, E.
    Macias, R. I. R.
    Robledo, V. S.
    Hernandez-Iglesias, J.
    Gonzalez-Hernandez, A.
    Bujanda, L.
    Banales, J.
    Marin, J. J. G.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S431 - S432
  • [8] INTERACTION BETWEEN GENETIC VARIANTS IN THE TRANSPORTERS, OCT1 AND MATE1, AND GLYCEMIC RESPONSE TO METFORMIN
    Yee, S.
    Jenkins, G.
    Joshki, P.
    Savic, R. M.
    Mefford, J. A.
    Hemmes, M. A.
    Witte, J. S.
    Wilke, R. A.
    McCarty, C. A.
    Davis, R. L.
    Giacomini, K. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S2 - S2
  • [9] INTERACTION BETWEEN GENETIC VARIANTS IN THE TRANSPORTERS, OCT1 AND MATE1, AND GLYCEMIC RESPONSE TO METFORMIN.
    Yee, S.
    Jenkins, G.
    Joshki, P.
    Savic, R. M.
    Mefford, J. A.
    Hemmes, M. A.
    Witte, J. S.
    Wilke, R. A.
    McCarty, C. A.
    Davis, R. L.
    Giacomini, K. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S37 - S37
  • [10] Relationship between CD34 expression and clinicopathologic characteristics in hepatocellular carcinoma and intrahepatic cholangiocarcinoma
    Xian, ZH
    Cong, WM
    Xhang, SH
    Wu, WQ
    Dong, H
    Wu, MC
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 124 (04) : 653 - 653
12345